Merit Medical Has To Rebuild Some Confidence In The Growth Story

Merit Medical (MMSI) has experienced recent challenges, including tariff impacts and a Wrapsody reimbursement error, leading to performance below bull expectations. Despite these near-term headwinds, core operations remain fundamentally strong, and the Wrapsody reimbursement issue is projected to resolve by late 2025, supporting the company's long-term growth trajectory. With a new CEO and continued commitment to an M&A-driven strategy, MMSI shares are considered modestly undervalued, offering potential upside to $103-$116 by 2026 if Wrapsody delivers as anticipated.

Analysis

Merit Medical (MMSI) is navigating a period of near-term challenges that have tempered investor expectations over the past six months. The primary headwinds identified are the net-negative earnings impact from tariffs and a specific setback related to a reimbursement error for its Wrapsody device. Despite these issues, the company's core operations are described as remaining fundamentally strong. The resolution of the Wrapsody reimbursement issue is a key future catalyst, with a resolution anticipated by the end of 2025, which would preserve the product's long-term growth potential. While the impact of the new CEO, Martha Aronson, is still to be determined, the company's strategic direction appears unchanged, with a continued focus on M&A and operational improvements. From a valuation standpoint, MMSI shares are considered modestly undervalued, with a potential price range of $103–$116 projected for 2026, contingent on the successful delivery of the Wrapsody growth story.

Key Decisions for Investors

• Investors should weigh the company's fundamentally strong core operations against near-term headwinds from tariffs and the Wrapsody reimbursement delay, which present a long-term opportunity if execution risks are tolerated.
• Monitor for key catalysts, specifically any progress on the Wrapsody reimbursement resolution, which is expected by the end of 2025, as this is critical to achieving the projected $103–$116 valuation.
• Given the stock is viewed as modestly undervalued, current levels may represent an attractive entry point for those confident in management's ability to navigate the present challenges and deliver on the Wrapsody launch in 2026.